Cargando…
Non-malignant respiratory epithelial cells preferentially proliferate from resected non-small cell lung cancer specimens cultured under conditionally reprogrammed conditions
The “conditionally reprogrammed cells” (CRC) method, using a Rho kinase inhibitor and irradiated mouse fibroblast cells has been described for the efficient growth of cells from malignant and non-malignant samples from primary tumor and non-malignant sites. Using the CRC method, four institutions in...
Autores principales: | Gao, Boning, Huang, Chunxian, Kernstine, Kemp, Pelekanou, Vasiliki, Kluger, Yuval, Jiang, Tingting, Peters-Hall, Jennifer R, Coquelin, Melissa, Girard, Luc, Zhang, Wei, Huffman, Kenneth, Oliver, Dwight, Kinose, Fumi, Haura, Eric, Teer, Jamie K, Rix, Uwe, Le, Anh T, Aisner, Dara L, Varella-Garcia, Marileila, Doebele, Robert C, Covington, Kyle R, Hampton, Oliver A, Doddapaneni, Harsha V, Jayaseelan, Joy C, Hu, Jianhong, Wheeler, David A, Shay, Jerry W, Rimm, David L, Gazdar, Adi, Minna, John D |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5355251/ https://www.ncbi.nlm.nih.gov/pubmed/28052041 http://dx.doi.org/10.18632/oncotarget.14366 |
Ejemplares similares
-
Stratification of non-small cell lung cancer patients for therapy with epidermal growth factor receptor inhibitors: the EGFR fluorescence in situ hybridization assay
por: Varella-Garcia, Marileila
Publicado: (2006) -
Resistance to ROS1 Inhibition Mediated by EGFR Pathway Activation in Non-Small Cell Lung Cancer
por: Davies, Kurtis D., et al.
Publicado: (2013) -
Activation of RAS family members confers resistance to ROS1 targeting drugs
por: Cargnelutti, Marilisa, et al.
Publicado: (2014) -
Collateral sensitivity networks reveal evolutionary instability and novel treatment strategies in ALK mutated non-small cell lung cancer
por: Dhawan, Andrew, et al.
Publicado: (2017) -
Off-target based drug repurposing opportunities for tivantinib in acute myeloid leukemia
por: Kuenzi, Brent M., et al.
Publicado: (2019)